Will submit two NDAs over the next 12 months, including the oral antibiotic Unasyn (sultamicillin) and an azolide antibiotic azithromycin, firm reported at April 27 annual meeting. An injectable form of Unasyn (sulbactam/ampicillin) was approved for U.S. marketing in December 1987. Pfizer currently has eight NDAs pending at FDA, the company said. Among drugs pending agency approval are the antifungal Diflucan (fluconazole), filed March 1, Xomen-E5, Xoma's monoclonal antibody-based treatment for gram negative sepsis developed in conjunction with Pfizer, Procardia XL, Minipress XL, the vasodilator Cardura (see related story), Norvasc, the anti-depressant sertraline, and the selective antihistamine cetirizine.
You may also be interested in...
The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.
Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.
No device-related warning letters were released by the US FDA the week of 29 September.